Belgium is home to UCB, Janssen Pharmaceutica, and Eurofins, and hosts many activities of the EMA. The pharmaceutical sector accounts for nearly 20% of Belgian exports. Marketing authorisation dossiers, patient information leaflets, labelling, and pharmacovigilance reports: every document demands rigorous medical translation that complies with European regulatory requirements.
Pharmaceutical documents requiring translation
The pharmaceutical sector generates a considerable volume of multilingual documentation. In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) requires that many documents be available in both French and Dutch, in line with the regulatory framework of this three-language-community country.
- Patient Information Leaflets (PIL): mandatory in both French and Dutch for any medicinal product marketed in Belgium
- Summary of Product Characteristics (SmPC): a technical document intended for healthcare professionals, translated in accordance with EMA guidelines
- Primary and secondary labelling: carton, vial, ampoule - mandatory French and Dutch mentions for the Belgian market
- Pharmacovigilance reports (PSUR, PADER): submitted to the FAMHP and the EMA as part of post-marketing surveillance
- Clinical trial protocols and reports: informed consents, investigator brochures, CSR reports
- Standard Operating Procedures (SOPs): quality documentation for manufacturing sites in Belgium
ICH CTD and marketing authorisation dossier
The Marketing Authorisation (MA) dossier follows the ICH Common Technical Document (CTD) format structured in five modules. Translating this dossier requires in-depth knowledge of European regulatory terminology and the specific requirements of both the EMA and the FAMHP.
Module 1, which is country-specific, must be translated in full into both French and Dutch for Belgium. Modules 2 to 5, drafted in English in accordance with ICH conventions, may require partial translations for certain national procedures. TranslateBE has translators specialised in regulatory pharmacology who are familiar with CTD language and EMA/ICH guidelines Q1 to Q14.
TranslateBE
Pharmaceutical translation in Belgium
Translators specialised in regulatory pharmacology. FAMHP, EMA and ICH CTD expertise. Free quote within 2 hours.
Rates and turnaround for pharmaceutical translation
Pharmaceutical translation is a high-value specialty. Rates vary according to terminological complexity, volume and urgency of the dossier.
- Standard patient information leaflet (PIL): from €180 for a document of 1,500 to 2,000 words, delivery in 3 to 5 business days
- SmPC: from €250 depending on length, delivery in 5 to 7 business days with specialist review
- Full MA dossier (Module 1): bespoke quote based on volume, batch delivery possible to respect your regulatory milestones
- 48-hour express option: available for urgent leaflets and responses to FAMHP queries
All our pharmaceutical translators work in translator-specialist reviewer pairs, guaranteeing terminological consistency across the entire dossier. We use translation memories and sector glossaries to ensure terminological continuity between your documents.
FAQ
Frequently asked questions
Is it mandatory to translate the patient leaflet into French for the Belgian market?
Yes, it is a legal obligation. Any medicinal product marketed in Belgium must have a patient information leaflet (PIL) in both French and Dutch. This requirement is imposed by Directive 2001/83/EC and enforced by the FAMHP. A German-language leaflet is also required for products distributed in the German-speaking Community. Non-compliant translations can result in a refused marketing authorisation or market withdrawal.
Who validates translations for the FAMHP?
The FAMHP does not mandate a specific approved translator, but it verifies the quality and compliance of translations submitted. In practice, it is essential to use translators specialised in regulatory pharmacology with thorough knowledge of EMA guidelines and the CTD format. TranslateBE provides revision by a second specialist translator and issues a certificate of translation on request.
What is the turnaround for translating a patient information leaflet?
A standard leaflet of 1,500 to 2,000 words is delivered in 3 to 5 business days including specialist review. For urgent situations - response to a FAMHP query or post-pharmacovigilance update - an express 48-hour option is available. For complete MA dossiers, we draw up a batch delivery schedule adapted to your regulatory milestones.